Get started
Author

K. Gary Barnette

The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial
2011 · James T. Dalton, Kester G. Barnette, et al. · Journal of Cachexia Sarcopenia and Muscle · 411
PDF
Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
2012 · Matthew R. Smith, Ronald A. Morton, et al. · The Journal of Urology · 159
Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
2010 · Matthew R. Smith, Ronald A. Morton, et al. · The Journal of Urology · 121
Toremifene Increases Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase 3 Clinical Study
2007 · M.R. Smith, S.B. Malkowicz, et al. · The Journal of Urology · 116
Toremifene Improves Lipid Profiles in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase III Study
2008 · Matthew R. Smith, S. Bruce Malkowicz, et al. · Journal of Clinical Oncology · 78
Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis
2022 · K. Gary Barnette, Michael S. Gordon, et al. · NEJM Evidence · 39
A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent
2022 · Mark C. Markowski, Ronald Tutrone, et al. · Clinical Cancer Research · 37
Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.
2021 · Carlo Palmieri, Hannah M. Linden, et al. · Journal of Clinical Oncology · 34
Factors Associated With Vertebral Fractures in Men Treated With Androgen Deprivation Therapy for Prostate Cancer
2011 · Philip J. Saylor, Ronald A. Morton, et al. · The Journal of Urology · 29
Toremifene citrate versus placebo for treatment of bone loss and other complications of androgen deprivation therapy in patients with prostate cancer
2004 · M. S. Steiner, A. Patterson, et al. · Journal of Clinical Oncology · 26
Ostarine increases lean body mass and improves physical performance in healthy elderly subjects: Implications for cancer cachexia patients
2007 · W. Evans, M. R. Smith, et al. · Journal of Clinical Oncology · 19
Racial Differences in Bone Mineral Density and Fractures in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
2012 · Alicia K. Morgans, Michael L. Hancock, et al. · The Journal of Urology · 18
Glutathione S-Transferase in Human Endometrium: Quantitation and Interindividual Variability in Isoform Content
1999 · K. Gary Barnette, Mohamadi A. Sarkar, et al. · Gynecologic and Obstetric Investigation · 10
Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.
2022 · Elgene Lim, Adam Brufsky, et al. · Journal of Clinical Oncology · 8
673: Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) Remain at High Risk for Prostate Cancer Regardless of whether HGPIN is Detected on Subsequent Biopsies
2005 · Daniel Burzon, Richard J. Kahnoski, et al. · The Journal of Urology · 6
Prevalence of osteoporosis and osteopenia during androgen deprivation (ADT) for prostate cancer: Baseline data from a large randomized controlled trial
2007 · S. B. Malkowicz, F. Chu, et al. · Journal of Clinical Oncology · 5
690: Toremifene for the Prevention of Prostate Cancer Among 514 Men with High-Grade Prostatic Intraepithelial Neoplasia (PIN): Results of a Double-Blind, Placebo-Controlled Phase IIB Trial
2005 · David Price, Barry Stein, et al. · The Journal of Urology · 5
PDF
2066-LB: Potential to Optimize Weight Loss with Enobosarm—Meta-analysis of Body Composition from Three Randomized Clinical Trials Support the Ability of Enobosarm to Preserve Muscle while Reducing Fat
2024 · JEFFREY CRAWFORD, ADRIAN S. DOBS, et al. · Diabetes · 4
Clinical study of VERU-111, an oral cytoskeletal disruptor, in metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.
2021 · Mark Christopher Markowski, Mario A. Eisenberger, et al. · Journal of Clinical Oncology · 4
Toremifene citrate increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer
2006 · M. R. Smith, F. Chu, et al. · Journal of Clinical Oncology · 4
LB1530. Clinical Benefit of Oral sabizabulin for Hospitalized Adults with CoVID-19 on Supplemental Oxygen
2022 · Tara L Gonzales, Paula Skarda, et al. · Open Forum Infectious Diseases · 3
Phase 3 VERACITY clinical study of sabizabulin in men with metastatic castration-resistant prostate cancer who have progressed on an androgen receptor targeting agent.
2022 · Robert Dreicer, Franklin Chu, et al. · Journal of Clinical Oncology · 3
Phase 3 VERACITY clinical study of sabizabulin in men with metastatic castrate resistant prostate cancer who have progressed on an androgen receptor targeting agent.
2022 · Robert Dreicer, Franklin Chu, et al. · Journal of Clinical Oncology · 3
Effect of GTx-024, a selective androgen receptor modulator (SARM), on stair climb performance and quality of life (QOL) in patients with cancer cachexia.
2010 · M. S. Steiner, K. G. Barnette, et al. · Journal of Clinical Oncology · 3
VERU-111, an oral cytoskeleton disruptor, to treat men with metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.
2021 · Mark Christopher Markowski, Ronald F. Tutrone, et al. · Journal of Clinical Oncology · 2
Works count: 54
Citation count: 1,154
H-index: 12
I10-index: 13
Year
Topic
Type